
Source: Novadel via BusinessWireThe NDA was filed under Section 505(b)(2) of the Food, Drug and Cosmetic Act. If approved by the FDA, Hana targets commercial launch of Zensana™ in the United States in the first half of 2007.
NovaDel is due an additional milestone payment upon product approval, and royalties on the sales of the product. NovaDel retains worldwide rights to Zensana™ outside of North America.






Comment Preview